Schroder Investment Management Group Acquires 374,213 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Schroder Investment Management Group grew its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 86.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 805,445 shares of the specialty pharmaceutical company’s stock after purchasing an additional 374,213 shares during the period. Schroder Investment Management Group owned approximately 1.63% of KalVista Pharmaceuticals worth $6,758,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of KALV. State Street Corp grew its position in KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after acquiring an additional 515,179 shares during the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at approximately $634,000. Barclays PLC grew its holdings in shares of KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock valued at $778,000 after purchasing an additional 54,257 shares during the last quarter. SG Americas Securities LLC increased its position in KalVista Pharmaceuticals by 10.0% during the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company’s stock worth $123,000 after purchasing an additional 1,319 shares in the last quarter. Finally, FMR LLC lifted its stake in KalVista Pharmaceuticals by 22.9% in the 3rd quarter. FMR LLC now owns 66,423 shares of the specialty pharmaceutical company’s stock valued at $769,000 after purchasing an additional 12,397 shares during the last quarter.

Analysts Set New Price Targets

Several brokerages have recently issued reports on KALV. TD Cowen began coverage on shares of KalVista Pharmaceuticals in a report on Tuesday, January 7th. They set a “buy” rating and a $30.00 price target for the company. Bank of America started coverage on KalVista Pharmaceuticals in a report on Wednesday, December 18th. They issued a “buy” rating and a $22.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Wednesday, March 26th. Finally, JMP Securities started coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, KalVista Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Stock Performance

Shares of KALV stock opened at $10.71 on Friday. The company has a market cap of $532.46 million, a P/E ratio of -2.94 and a beta of 0.39. The stock has a 50 day simple moving average of $10.82 and a two-hundred day simple moving average of $10.27. KalVista Pharmaceuticals, Inc. has a fifty-two week low of $7.30 and a fifty-two week high of $15.50.

Insider Buying and Selling

In other news, CEO Benjamin L. Palleiko sold 6,669 shares of the stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $11.97, for a total value of $79,827.93. Following the completion of the sale, the chief executive officer now directly owns 287,811 shares of the company’s stock, valued at $3,445,097.67. This represents a 2.26 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Venrock Healthcare Capital Par bought 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 12th. The shares were bought at an average cost of $9.23 per share, for a total transaction of $923,000.00. Following the transaction, the insider now owns 5,217,285 shares of the company’s stock, valued at $48,155,540.55. The trade was a 1.95 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 236,055 shares of company stock worth $2,162,146 and have sold 17,292 shares worth $184,625. 10.50% of the stock is currently owned by company insiders.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).